3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
4
Triple Negative Breast Neoplasms
3
Obesity
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Insulin Resistance
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Breast Cancer Female
2
Brain Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sleep Wake Disorders
1
Sezary Syndrome
1
Rectal Neoplasms
1
Racism
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
selpercatinib
2
exemestane
2
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Docetaxel
2
AZD9833
2
tucatinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
entinostat
1
elacestrant
1
atezolizumab
1
alectinib
1
Zoledronic Acid
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
Sodium Chloride
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Imlunestrant
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Metformin
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled